The drastic cost cuts and pipeline narrowing signal a cash-constrained company betting its future on a single mid-2027 readout. Monitor cash runway disclosures in upcoming filings and any financing needs before the Phase 2b data.
Price Chart
Executive Summary
Enlivex announced a cost reduction plan to wind down non-clinical R&D, cut workforce by ~60%, and reduce management/CEO salaries by 20-40%, aiming to focus resources on its Phase 2b trial of Allocetra for knee osteoarthritis. Topline six-month data is expected by mid-2027. The plan is designed to substantially reduce cash burn but reflects a significant narrowing of the company's pipeline and a distressed operational posture.
Key Facts
- Workforce reduced by approximately 60%
- Management salaries cut by 20%, CEO salary cut by 40%
- All non-clinical R&D activities wound down immediately
- Phase 2b topline six-month data expected by mid-2027
- FDA granted RMAT designation for Allocetra in July 2026
- Phase 1/2a showed statistically significant improvements in pain and function vs placebo at 3 and 6 months
Financial Impact
Cash burn substantially reduced; restructuring charges and savings amounts not disclosed
Risk Factors
- Cash runway may be insufficient to reach mid-2027 topline data without additional financing
- Phase 2b may fail to replicate Phase 1/2a results, leaving no pipeline
- Workforce reduction could impair trial execution or regulatory capabilities
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383415 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 22, 2026 4d ago | Press Release | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 19, 2026 7d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Oct 19, 2026 7d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | $2.56 (+398.99%) |
Sep 22, 2026 4w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | $2.56 (+296.78%) |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | $2.56 (+62.33%) |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | $2.56 (+31.53%) |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | $2.56 (+13.99%) |
Jul 28, 2026 12w ago | 6-K | $2.24 $2.17 | ▲ +3.13% | ▲ +5.39% | $2.56 (−14.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers